Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASTRAL-5: Sofosbuvir/Velpatasvir in HIV/HCV Coinfection
NCT02480712Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Jul 2015
- Primary completion
- Apr 2016
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of sofosbuvir, velpatasvir in hepatitis C (HCV), sponsored by Gilead Sciences. Started Jul 2015; status: completed.
02
Drugs
sofosbuvirvelpatasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02480712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02480712.